Barbara P. Yawn

Prof. Barbara P. Yawn


Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2007 in Mayo Clinic Proceedings
Verified
Journal Article
Closed access
BYBarbara P. Yawn
Barbara P. Yawn
PSPatricia Saddier
Patricia Saddier
PWPeter C. Wollan
Peter C. Wollan
JSJennifer L. St. Sauver
Jennifer L. St. Sauver
MKMarge J. Kurland
Marge J. Kurland
LSLina S. Sy
Lina S. Sy

2 March 2021 in Human Vaccines & Immunotherapeutics
Verified
Journal Article
Open access
DODésirée van Oorschot
Désirée van Oorschot
HVHilde Vroling
Hilde Vroling
EBEveline Bunge
Eveline Bunge
JDJohn Diaz-Decaro
John Diaz-Decaro
DCDesmond Curran
Desmond Curran
BYBarbara P. Yawn
Barbara P. Yawn
We conducted a systematic review to characterize the incidence rate of herpes zoster (HZ) in the general population, specifically in individuals ≥50 years of age. A total of 69 publications were included in the review. We found a cumulative incidence of HZ ranging from 2.9–19.5 cases per 1,000 population and an incidence rate of HZ ranging from 5.23–10.9 cases per 1,000 person-years. The cumulative incidence (3.22–11.2 versus 2.44–8.0 cases per 1,000 population) and incidence rates (6.05–12.8 versus 4.30–8.5 cases per 1,000 person-years) were higher in females than males. Studies revealed a trend of increasing incidence of HZ with increasing age and over time. Variations in incidence estimates can be attributed to the various study designs, case ascertainments, age distributions of the population and year of the study. HZ is associated with a substantial disease burden and is expected to increase due to population aging.

1 February 2011 in Mayo Clinic Proceedings
Verified
Journal Article
Closed access
BYBarbara P. Yawn
Barbara P. Yawn
PWPeter C. Wollan
Peter C. Wollan
MKMarge J. Kurland
Marge J. Kurland
JSJennifer L. St. Sauver
Jennifer L. St. Sauver
PSPatricia Saddier
Patricia Saddier

1 June 2013 in Mayo Clinic Proceedings
Verified
Journal Article
Closed access
BYBarbara P. Yawn
Barbara P. Yawn
PWPeter C. Wollan
Peter C. Wollan
JSJennifer L. St. Sauver
Jennifer L. St. Sauver
LBLinda C. Butterfield
Linda C. Butterfield

15 March 2017 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Closed access
FMFernando J. Martinez
Fernando J. Martinez
DMDavid Mannino
David Mannino
NLNancy Kline Leidy
Nancy Kline Leidy
KMKaren G. Malley
Karen G. Malley
EBElizabeth D. Bacci
Elizabeth D. Bacci
FGfor the High-Risk-COPD Screening Study Group
for the High-Risk-COPD Screening Study Group
Rationale: Chronic obstructive pulmonary disease (COPD) is often unrecognized and untreated. Objectives: To develop a method for identifying undiagnosed COPD requiring treatment with currently available therapies (FEV1 <60% predicted and/or exacerbation risk). Methods: We conducted a multisite, cross-sectional, case-control study in U.S. pulmonary and primary care clinics that recruited subjects from primary care settings. Cases were patients with COPD and at least one exacerbation in the past year or FEV1 less than 60% of predicted without exacerbation in the past year. Control subjects were persons with no COPD or with mild COPD (FEV1 ≥60% predicted, no exacerbation in the past year). In random forests analyses, we identified the smallest set of questions plus peak expiratory flow (PEF) with optimal sensitivity (SN) and specificity (SP). Measurements and Main Results: PEF and spirometry were recorded in 186 cases and 160 control subjects. The mean (SD) age of the sample population was 62.7 (10.1) years; 55% were female; 86% were white; and 16% had never smoked. The mean FEV1 percent predicted for cases was 42.5% (14.2%); for control subjects, it was 82.5% (15.7%). A five-item questionnaire, CAPTURE (COPD Assessment in Primary Care to Identify Undiagnosed Respiratory Disease and Exacerbation Risk), was used to assess exposure, breathing problems, tiring easily, and acute respiratory illnesses. CAPTURE exhibited an SN of 95.7% and an SP of 44.4% for differentiating cases from all control subjects, and an SN of 95.7% and an SP of 67.8% for differentiating cases from no-COPD control subjects. The PEF (males, <350 L/min; females, <250 L/min) SN and SP were 88.0% and 77.5%, respectively, for differentiating cases from all control subjects, and they were 88.0% and 90.8%, respectively, for distinguishing cases from no-COPD control subjects. The CAPTURE plus PEF exhibited improved SN and SP for all cases versus all control subjects (89.7% and 78.1%, respectively) and for all cases versus no-COPD control subjects (89.7% and 93.1%, respectively). Conclusions: CAPTURE with PEF can identify patients with COPD who would benefit from currently available therapy and require further diagnostic evaluation. Clinical trial registered with clinicaltrials.gov (NCT01880177).

1 April 2009 in Pain Medicine
Verified
Journal Article
Open access
PDF file
BYBarbara P. Yawn
Barbara P. Yawn
PWPeter C. Wollan
Peter C. Wollan
TWToby N. Weingarten
Toby N. Weingarten
JWJames C. Watson
James C. Watson
WHW. Michael Hooten
W. Michael Hooten
LML. Joseph Melton
L. Joseph Melton
Background. Neuropathic pain is reported to be common based on studies from specialty centers and survey studies. However, few prevalence estimates ha